ORLANDO, Fla., Sept. 21 /PRNewswire-FirstCall/ -- The Wall Street Reporter financial publication recently interviewed Vein Associates Of America’s Chief Operating Officer and acting Chief Executive Officer, Eric Luetkemeyer. The interview, located on the publication’s website under CEO profiles, can be found by visiting http://www.wallstreetreporter.com .
During the interview Mr. Luetkemeyer spoke of the recent changes in the corporate infrastructure, the huge market for vein treatment and the company’s proprietary technology. “Our focus is on growth,” says Mr. Luetkemeyer. “We’ve recently opened eight clinics nationwide and the Company is planning to have thirty clinics up and running by 2006.”
“It’s an aggressive plan but the timing on vein treatment has proven itself,” says Mr. Luetkemeyer. “In January, when the Medicare reimbursement rates became more favorable, we knew we had to move quickly to be the first nationwide chain of vascular clinics.”
The interview went on to cover Mr. Luetkemeyer’s professional experience, trends in shaping the company and the potential market opportunity for Vein Associates. “We have just started to rollout,” says Mr. Luetkemeyer. “The growth is soon to come and the market is huge. We have the experienced management team and expert physicians to offer the medical services that over 75% of the population will be looking for.”
About Vein Associates Of America, Inc.
Vein Associates Of America, Inc. operates advanced and well-equipped medical facilities devoted exclusively to the treatment of vein disease. The Company has established and is rapidly expanding highly specialized, professional medical treatment centers comprised of new and effective techniques available in vein treatment. For more information, please visit our website: http://www.vrccorp.com .
Safe Harbor Statement: Forward-looking statements in this release with respect to Vein Associates Of America, Inc. business, financial condition and results of operations, as well as matters of timing and the prospective terms of the transaction described are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond Vein Associates Of America’s control with respect to market acceptance of their technology and/or products, whether financing will be available, the effect of the application of acquisition accounting policies as well as certain other risk factors which are and may be detailed from time to time in Vein Associates Of America’s filings with the Securities and Exchange Commission.
Vein Associates Of America, Inc.
CONTACT: Jamison Teske, office, +1-612-331-3586, or direct,+1-612-238-3014, or fax, +1-612-238-3000, or jamison@linnihanfoy.com , orNeal Linnihan, office, +1-612-331-3586, or direct, +1-612-238-3001, or fax,+1-612-238-3000, or neal@linnihanfoy.com , both for Vein Associates OfAmerica, Inc.